Albireo Appoints New Members to Board of Directors
– Habib Dable, Former President and CEO of Acceleron Pharma, and Susan Alesina, Vice President,…
News
The Greenrose Holding Company to Hold Second Quarter 2022 Conference Call on August 15, 2022 at 5:00 p.m. ET
AMITYVILLE, N.Y., Aug. 10, 2022 (GLOBE NEWSWIRE) — The Greenrose Holding Company Inc. (OTC: GNRS,…
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones
Planned re-submission of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) to U.S. Food and…
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial
Trial to Continue as Planned SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals,…
Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global…
Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer
Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient…
LianBio Completes Enrollment in Pivotal Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients
• Topline data expected mid-2023 • EXPLORER-CN trial, together with PK study conducted in healthy…
Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research
– FORCE™ Platform Achieves Enhanced Exon Skipping and Prolonged Dystrophin Restoration in Duchenne in vivo mdx…
BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
– NULIBRY is the first and only approved therapy in the United States (U.S.) and…
TOWER ONE WIRELESS ANNOUNCES FOURTEEN TOWERS COMPLETED – ADDITIONAL NON-CANCELLABLE RENT OF $2,300,000
TOWER ONE CONSTRUCTION UPDATE FOR THE MONTH OF JULY 2022 VANCOUVER, BC, CANADA, Aug. 10,…
Kamada to Announce Second Quarter and First Half Ended June 30, 2022 Financial Results and Host Conference Call on August 17, 2022
REHOVOT, Israel and HOBOKEN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ &…
Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with…
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates…
Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
– Patients with MTAP-deleted solid tumors being actively enrolled in ongoing Phase 1/2 trial of…
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Completed agreement for strategic collaboration to jointly develop and commercialize CLN-081 with Taiho Pharmaceutical Presented…
Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update
Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLC Announced successful production of…
IsoPlexis Reports Second Quarter 2022 Financial Results
BRANFORD, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) — IsoPlexis Corporation (Nasdaq: ISO), a company empowering…
PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Signed Exclusive Licensing Agreement for Commercialization of D-PLEX100 in Europe for Potentially Over $110 Million…
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp) now approved…
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874
– Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022…